W
William W. Freimuth
Researcher at Pfizer
Publications - 12
Citations - 437
William W. Freimuth is an academic researcher from Pfizer. The author has contributed to research in topics: Delavirdine & Didanosine. The author has an hindex of 8, co-authored 12 publications receiving 426 citations. Previous affiliations of William W. Freimuth include Upjohn & Human Genome Sciences.
Papers
More filters
Journal ArticleDOI
Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus—Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359
Roy M. Gulick,X. Joan Hu,X. Joan Hu,Susan A. Fiscus,Courtney V. Fletcher,Richard Haubrich,Hailong Cheng,Edward P. Acosta,Edward P. Acosta,Stephen W. Lagakos,Ronald Swanstrom,William W. Freimuth,William W. Freimuth,Sally Snyder,Charlotte Mills,Margaret A. Fischl,Carla Pettinelli,David Katzenstein +17 more
TL;DR: Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen.
Journal ArticleDOI
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
Lisa M. Demeter,Robert W. Shafer,Patricia M. Meehan,Jeanne Holden-Wiltse,Margaret A. Fischl,William W. Freimuth,Michael F. Para,Richard C. Reichman +7 more
TL;DR: The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy and K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominantreverse transcriptase mutations.
Journal ArticleDOI
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
Richard Furie,Michelle Petri,Vibeke Strand,Dafna D. Gladman,Z John Zhong,Z John Zhong,William W. Freimuth,William W. Freimuth,Bliss Study Groups +8 more
TL;DR: Overall, SRI response in patients with active, autoantibody-positive SLE was associated with improvements in clinical, laboratory and patient-reported outcome measures, indicating that SRI responders were associated with a global benefit.
Journal ArticleDOI
Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen.
Bruce L. Gilliam,John R. Dyer,Susan A. Fiscus,Cheryl Marcus,Susan Zhou,Lynne Wathen,William W. Freimuth,Myron S. Cohen,Joseph J. Eron +8 more
TL;DR: Initiation of reverse transcriptase inhibitor therapy effectively reduces shedding of HIV-1 in semen and may therefore reduce the spread of infection within populations.
Journal ArticleDOI
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261)
Gerald Friedland,Richard B. Pollard,Brigitte P. Griffith,Michael Hughes,Gene D. Morse,Roland L. Bassett,William W. Freimuth,Lisa M. Demeter,Elizabeth Connick,Thomas Nevin,Martin S. Hirsch,Margaret A. Fischl +11 more
TL;DR: A phase II, randomized, double-blind, multicenter trial comparing the three-drug combination of delavirdine with zidovudine and didanosine to two-drug combinations of these drugs was performed in this paper.